Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TDM-Guided Adalimumab Optimization in Crohn's Disease
NCT03261102Active, not recruiting
- Sponsor
- Waqqas Afif
- Start
- Jan 2017
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of adalimumab in Crohn's disease (2 arms), sponsored by Waqqas Afif. Primary endpoint: Proportion of subjects who achieved remission at 12 weeks. Started Jan 2017; status: active, not recruiting.
02
Drugs
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NCT03261102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03261102.